DP-IMRT Pancreas

About this trial

The study treatment is radiotherapy – different doses of radiotherapy will be given to patients. The first group of patients will receive the lowest dose (dose level 1) – this is the dose delivered to patients as standard of care. If the treatment does not cause serious side effects, it will be given to the next group of patients enrolled at a higher dose (dose level 2) – this is called ‘dose escalation’. If this higher dose of treatment does not cause serious side effects, the next group of patients will receive a higher dose (dose level 3). The doses will continue to increase for every group of patients, as long as no serious side effects occur. If this happens, the study is halted. Once the optimum dose level has been reached, a larger cohort of patients will all receive this dose.

Patient Profile

Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma.

Where’s this trial being run?

St Luke’s Radiation Oncology Network @ St Luke’s Hospital and St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: DP-IMRT Pancreas
Number: 17-12
Full Title:

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas): A non-randomised Phase I/II study of dose escalated hypofractionated Dose-Painted Intensity Modulated
Radiotherapy (DP-IMRT) in resectable/borderline resectable pancreatic adenocarcinoma

Principal Investigator: Dr Gerard McVey
Type: In-House
Sponsor:

Cancer Trials Ireland

Recruitment Started: Global: January 2024
Ireland: January 2024
Global Recruitment Target:
Ireland Recruitment Target: Phase I = minimum of 6, maximum of 18 patients. Phase II = 49 patients